| Zhang, Jin li |
NCT03359694: Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer |
|
|
| Not yet recruiting | 3 | 300 | RoW | DT group, Pegylated liposomal doxorubicin and Docetaxel, ET group, Conventional doxorubicin and Docetaxel, NX group, Navelbine and Xeloda | Tianjin Medical University Cancer Institute and Hospital | Susceptibility, Genetic, Chemotherapy Effect | 11/19 | 10/22 | | |
NCT04629846: Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel. |
|
|
| Completed | 3 | 517 | RoW | Trastuzumab, Herceptin®, QL1209, Recombinant anti-HER-2 domain Ⅱ humanized monoclonal antibody injection, Pertuzumab, Perjeta®, Docetaxel, Docetaxel injection, surgery | Qilu Pharmaceutical Co., Ltd. | Breast Cancer | 08/22 | 10/23 | | |
CLOVER, NCT03926091: Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer |
|
|
| Recruiting | 3 | 2172 | RoW | Docetaxel, docetaxel injection, Cyclophosphamide, Cyclophosphamide injection | Fudan University | Breast Cancer | 11/24 | 11/25 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
NCT03351062: Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer |
|
|
| Recruiting | 3 | 844 | RoW | Tamoxifen, Tamoxifen citrate, Toremifene, fareston | Chinese Anti-Cancer Association, Fudan University, Henan Cancer Hospital, The First Hospital of Jilin University, Southwest Hospital, China, First Hospital of China Medical University, Guangdong Provincial People's Hospital, Harbin Medical University, First Affiliated Hospital of Chongqing Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Jiangsu Provincial People's Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Zhejiang Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, Union hospital of Fujian Medical University, Hebei Tumor Hospital, Hunan Cancer Hospital, Affiliated Hospital of Qinghai University, Wuhan TongJi Hospital, Hainan People's Hospital, The Third Affiliated Hospital of Kunming Medical College., The Third Affiliated Hospital of Nanchang University | Breast Cancer Female | 12/25 | 12/25 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NCT06227117: Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer |
|
|
| Recruiting | 2 | 120 | RoW | Disitamab Vedotin Injection （18 weeks）, DV,RC48-ADC, Toripalimab （18weeks）, JS001, Carboplatin, Disitamab Vedotin Injection （12 weeks）, Sequential Epirubicin, Epirubicin, Sequential CTX, CTX, cyclophosphamide, Toripalimab （12weeks） | RemeGen Co., Ltd. | Breast Cancer | 12/25 | 12/26 | | |
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis |
|
|
| Active, not recruiting | 2 | 112 | Europe, US, RoW | Selinexor, Physician's Choice Treatment | Karyopharm Therapeutics Inc | Myelofibrosis | 01/25 | 01/25 | | |
|
|
NCT03955978: TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer |
|
|
| Active, not recruiting | 1 | 10 | US | TSR-042, Brachytherapy, Endometrial biopsy, Blood draw for immune response | Washington University School of Medicine, Tesaro, Inc. | Endometrial Cancer, Cancer of the Endometrium | 03/24 | 12/25 | | |
| Not yet recruiting | N/A | 402 | NA | S-ketamine, esketamine, normal saline, physiological saline | Beijing Obstetrics and Gynecology Hospital, China Health Promotion Foundation, Beijing Haidian Maternal and Child Health Hospital, Obstetrics & Gynecology Hospital of Fudan University, Fourth Hospital of Shijiazhuang City, Changzhi Maternal and Child Health Hospital, Linfen Maternity&Child Healthcare Hospital, Maternal and Child Health Hospital, Jiading District, Tongzhou Maternal and Child Healthcare Hospital of Beijing, Beijing Chaoyang District Maternal and Child Health Care Hospital | Anesthesia, Analgesia, Depression, Cesarean Section, Parturition | 12/21 | 07/22 | | |
NCT04940091: Epidural Analgesia and Maternal Fever During Labor |
|
|
| Recruiting | N/A | 780 | RoW | Epidural analgesia, No other intervention | Peking University First Hospital, Guangdong Women and Children Hospital, Tangshan Maternal and Child Health Hospital, Dongguan Maternal and Child Health Hospital, Beijing Haidian Maternal and Child Health Hospital, Beijing Fuxing Hospital, Fourth Hospital of Shijiazhuang City, Xiamen Maternity & Child Care Hospital | Epidural Analgesia, Analgesic Effect, Fever | 09/22 | 10/22 | | |
NCT04582955: Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy |
|
|
| Recruiting | N/A | 20 | RoW | Chidamide in combination with chemotherapy, Other Name: For Chidamide: HBI-8000, CS055 | Tianjin Medical University Cancer Institute and Hospital | Triple-negative Breast Cancer | 12/22 | 12/22 | | |
NCT02506361: Evaluation of the Relationship of TOP2α Expression and Effect of Non Dose-dense Chemotherapy for Breast Cancer |
|
|
| Recruiting | N/A | 800 | RoW | | Tianjin Medical University Cancer Institute and Hospital | Breast Cancer | 05/25 | 10/25 | | |
NCT05534854: Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes |
|
|
| Recruiting | N/A | 500 | RoW | Gene test | RenJi Hospital, Ruijin Hospital, Shanghai Zhongshan Hospital, Huashan Hospital, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Zhejiang Provincial People's Hospital, Tongji Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Shanghai 10th People's Hospital, First Affiliated Hospital, Sun Yat-Sen University, Peking University First Hospital | Renal Tumor Histology, Kidney Cancer, Renal Cell Carcinoma, Familial Renal Cancer, HLRCC, VHL Syndrome, BAP1 Tumor Predisposition Syndrome, FLCN Gene Mutation, ALK Gene Mutation, FH Gene Mutation, Birt-Hogg-Dube Syndrome, MET Gene Mutation, Cutaneous Leiomyoma, Cutaneous Leiomyomata With Uterine Leiomyomata | 08/25 | 08/25 | | |
| Lu, Wei |
UplighTED, NCT06307626: A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults with Thyroid Eye Disease. |
|
|
| Recruiting | 3 | 108 | Europe, Japan, US, RoW | Efgartigimod PH20 SC, Placebo PH20 SC | argenx | Thyroid Eye Disease | 02/26 | 10/27 | | |
NCT05251662: Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 90 | RoW | Sintilimab, IBI305, Bevacizumab Biosimilar, GEMOX | Tianjin Medical University Cancer Institute and Hospital | Intrahepatic Cholangiocarcinoma | 01/24 | 01/25 | | |
NCT05651672: Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations |
|
|
| Recruiting | 2 | 100 | RoW | Pemigatinib, Pemazyre | Tianjin Medical University Cancer Institute and Hospital | Gastrointestinal Cancer | 12/24 | 12/26 | | |
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 2 | 162 | RoW | BAT4406F Injection, BAT4406F Placebos | Bio-Thera Solutions | Optic Neuromyelitis Spectrum Disease | 05/25 | 05/26 | | |
NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 70 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Intrahepatic Cholangiocarcinoma (ICC) | 05/26 | 12/26 | | |
NCT06310590: Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 40 | RoW | NRT6003 Injection, Yttrium-90 carbon microspheres | Chengdu New Radiomedicine Technology Co. LTD. | Unresectable Hepatocellular Carcinoma | 10/25 | 10/25 | | |
NCT05776121: Study of ZB001 in Chinese Patients With Thyroid Eye Disease |
|
|
| Active, not recruiting | 1 | 17 | RoW | ZB001 for injection | Zenas BioPharma (USA), LLC | Thyroid Eye Disease | 10/24 | 10/24 | | |
NCT06047431: A Study of QL1706H in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 150 | NA | QL1706H | Qilu Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 12/24 | 12/25 | | |
| Recruiting | N/A | 120 | RoW | early APM, Early arthroscopic partial meniscectomy, delayed APM, delayed arthroscopic partial meniscectomy | The First People's Hospital of Jingzhou | Meniscus Tear | 12/22 | 12/22 | | |
NCT05711459: Bicyclol in the Treatment of Antineoplastic Drug-induced Liver Injury. |
|
|
| Recruiting | N/A | 5405 | RoW | Bicyclol tablets | Tianjin Medical University Cancer Institute and Hospital | Drug-Induced Acute Liver Injury | 05/23 | 05/24 | | |
NCT05215665: GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma |
|
|
| Recruiting | N/A | 146 | RoW | GEMOX Regimen, Lenvatinib, Toripalimab | Tianjin Medical University Cancer Institute and Hospital | Cholangiocarcinoma | 05/24 | 01/26 | | |
NCT06292715: Microwave Ablation With Splenic Artery Occlusion for Secondary Hypersplenism |
|
|
| Recruiting | N/A | 35 | RoW | microwave ablation of the spleen, Splenic artery balloon implantation | Tianjin Medical University Cancer Institute and Hospital | Secondary Hypersplenism | 12/25 | 12/26 | | |
NCT05791604: The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics |
|
|
| Recruiting | N/A | 60 | RoW | probiotics including B. lactis B420, B. lactis HN019, B. animalis Bb-12, L. rhamnosus GG, Prebiotics with galactomannan and oligofructose | Children's Hospital of Fudan University | Prader-Willi Syndrome | 03/26 | 07/26 | | |
| Wang, Changli |
RATIONALE-315, NCT04379635: Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Active, not recruiting | 3 | 453 | RoW | Tislelizumab, BGB-A317, Cisplatin injection, Paclitaxel injection, Pemetrexed Disodium, Placebos, Carboplatin | BeiGene | Non Small Cell Lung Cancer | 06/25 | 11/25 | | |
|
| Recruiting | 3 | 390 | RoW | Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection, Experimental, placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection, Active Comparator | 3D Medicines (Sichuan) Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 09/27 | | |
NCT04965831: Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT) |
|
|
| Not yet recruiting | 2 | 40 | NA | Furmonertinib, AST2818 | Tianjin Medical University Cancer Institute and Hospital, Allist Pharmaceuticals, Inc. | Lung Adenocarcinoma | 03/23 | 05/26 | | |
NCT04530227: Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC |
|
|
| Recruiting | 2 | 30 | RoW | Biological: Camrelizumab, SHR-1210, Pemetrexed, Pemetrexed Disodium, Nab-paclitaxel, Paclitaxel for Injection（Albumin Bound） | Tianjin Medical University Cancer Institute and Hospital | Early Stage Non-small Cell Lung Cancer | 06/25 | 12/25 | | |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
NCT05088967: Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer |
|
|
| Terminated | 1 | 6 | RoW | IBI110, sintilimab | Innovent Biologics (Suzhou) Co. Ltd. | Non-small Cell Lung Cancer (NSCLC) | 12/21 | 12/23 | | |
| Guo, Zhi |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT06004856: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia |
|
|
| Recruiting | 3 | 195 | RoW | Orelabrutinib, Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Primary Immune Thrombocytopenia (ITP) | 12/25 | 04/26 | | |
NCT05895409: A Multicenter Prospective Study of Risk Factors in Progressive Pulmonary Fibrosis |
|
|
| Recruiting | N/A | 610 | RoW | | Qianfoshan Hospital | Interstitial Lung Disease | 06/26 | 06/28 | | |
| Xing, Wenge |
NCT06581107: Validate the Safety and Feasibility of the CT-guided Interventional Robot in Percutaneous Lung Cryablation Procedures |
|
|
| Not yet recruiting | N/A | 20 | RoW | CT-fluoroscopy guided master-slave intervetional robot-assisted lung Cryoablation | Tianjin Medical University Cancer Institute and Hospital, Wuhan United Imaging Surgical co., ltd. | Lung Cancer, Thoracic Cancer | 12/24 | 02/25 | | |
| Ba, Yi |
NCT03366883: Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC |
|
|
| Not yet recruiting | 3 | 420 | RoW | Paclitaxel, Cisplatin Plus 5-FU (TCF), radiochemotherapy | Tianjin Medical University Cancer Institute and Hospital, Shanghai Chest Hospital, Henan Cancer Hospital, The First Affiliated Hospital with Nanjing Medical University, First Affiliated Hospital of Chongqing Medical University, The First Affiliated Hospital of Anhui Medical University | Esophageal Cancer Stage IIB, Esophageal Cancer Stage III | 02/18 | 12/22 | | |
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
HLX10-006-GCneo, NCT04139135: A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer |
|
|
| Recruiting | 3 | 642 | RoW | HLX10, Recombinant humanized anti-PD-1 monoclonal antibody injection, Placebos | Shanghai Henlius Biotech | Gastric Cancer | 10/23 | 10/24 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NCT04555304: Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy |
|
|
| Not yet recruiting | 2 | 81 | NA | KH903 + Paclitaxel, Placebo + Paclitaxel | Chengdu Kanghong Biotech Co., Ltd. | Gastric Cancer, Gastroesophageal Cancer | 01/22 | 01/22 | | |
NCT05035381: PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 10 | RoW | Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen, Bevacizumab, Irinotecan, Fluorouracil, Leucovorin | Tianjin Medical University Cancer Institute and Hospital | MSI-H Advanced Colorectal Cancer | 12/22 | 12/22 | | |
NCT04969029: Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations |
|
|
| Recruiting | 2 | 30 | RoW | Tirelizumab | Tianjin Medical University Cancer Institute and Hospital | Immunotherapy, Adjuvant Therapy, Colon Cancer, MSI-H | 12/23 | 12/24 | | |
NCT06383559: Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients |
|
|
| Recruiting | 2 | 39 | RoW | Lenvatinib and Sintilimab | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer | 07/26 | 09/26 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT06430827: Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma |
|
|
| Not yet recruiting | 2 | 20 | RoW | irinotecan hydrochloride liposome injection, duoenyi, Capecitabine, Kapeitabin | Ba Yi, CSPC Ouyi Pharmaceutical Co., Ltd. | Biliary Tract Carcinoma | 12/24 | 12/25 | | |
TOBACO, NCT05077839: Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC |
|
|
| Recruiting | 2 | 184 | RoW | Trifluridine/Tipiracil, TAS-102 | Tianjin Medical University Cancer Institute and Hospital | First-line Treatment, Advanced Colorectal Cancer | 08/24 | 08/25 | | |
TQB2102-II-04, NCT06767800: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Benmelstobart/Penpulimab With or Without Capecitabine in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 168 | RoW | TQB2102 for injection+Benmelstobart, TQB2102 for injection+Benmelstobart+Capecitabine | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Gastroesophageal Adenocarcinoma | 09/26 | 09/27 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
NCT04229537: Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC |
|
|
| Not yet recruiting | 1 | 60 | NA | SCT-I10A, SCT200, Chemotherapy | Sinocelltech Ltd. | Esophageal Squamous Cell Carcinoma, Colorectal Cancer | 08/22 | 12/22 | | |
NCT05388279: A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors |
|
|
| Terminated | 1 | 3 | RoW | JS012, JS012 combine with chemotherapy | Shanghai Junshi Bioscience Co., Ltd. | Advanced or Metastatic Solid Tumors | 09/22 | 09/22 | | |
NCT04190823: A Study of RC98 in Subjects With Advanced Malignant Solid Tumors |
|
|
| Active, not recruiting | 1 | 63 | RoW | RC98, RC98 for Injection | RemeGen Co., Ltd. | Solid Tumors | 12/23 | 12/23 | | |
| Recruiting | 1 | 96 | RoW | TQB3454 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Solid Tumor or Hematologic Tumor | 12/22 | 12/22 | | |
NCT05221775: Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients |
|
|
| Recruiting | 1 | 18 | RoW | Lenvatinib | Tianjin Medical University Cancer Institute and Hospital | First-line Treatment, Advanced Gastric Carcinoma | 03/23 | 10/23 | | |
NCT05514158: To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) |
|
|
| Recruiting | 1 | 24 | RoW | RC48-ADC, RC48-ADC injection, RC98, RC98 injection | RemeGen Co., Ltd. | Gastric Cancer | 05/24 | 09/24 | | |
NCT05367635: A Study of SKB315 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 206 | RoW | SKB315 for injection | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Advanced Solid Tumors | 05/24 | 05/24 | | |
| Not yet recruiting | 1 | 96 | RoW | KM501 | Xuanzhu Biopharmaceutical Co., Ltd. | Advanced Solid Tumors | 12/26 | 12/27 | | |
| Zhang, Ti |
NCT03236649: The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects |
|
|
| Terminated | 3 | 89 | RoW | Icaritin, Sorafenib Tosylate Tablets | Beijing Shenogen Biomedical Co., Ltd, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Eastern Theater General Hospital,QinHuai District Medical Area, Peking University Cancer Hospital & Institute, Chinese PLA General Hospital, Beijing Hospital, General Hospital of Chinese Armed Police Forces, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Cancer Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Tianjin Medical University Cancer Institute and Hospital, The Fourth Hospital of Hebei Medical University, Hunan Cancer Hospital, The First Hospital of Jilin University, 307 Hospital of PLA, Fudan University, Henan Cancer Hospital, Jilin Provincial Tumor Hospital, First Affiliated Hospital of Harbin Medical University, First Affiliated Hospital Bengbu Medical College, The First Affiliated Hospital of Soochow University, Tongji Hospital, Beijing YouAn Hospital | Hepatocellular Carcinoma (HCC) | 02/22 | 02/22 | | |
NCT05435313: Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy |
|
|
| Active, not recruiting | 2 | 39 | RoW | HAIC, Fruquintinib, Tislelizumab, Raltitrexed, Oxaliplatin, Irinotecan | Fudan University | Colorectal Cancer | 01/24 | 02/24 | | |
NCT03982303: Phase I Study of Hemay102 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 39 | RoW | Hemay102 | Tianjin Hemay Oncology Pharmaceutical Co., Ltd | Patients With Advanced Stage Solid Tumors | 12/21 | 12/21 | | |
| Liang, Han |
NCT03355612: XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma |
|
|
| Not yet recruiting | 3 | 456 | NA | Apatinib, YN968D1, XELOX, Capecitabine and Oxaliplatin | Tianjin Medical University Cancer Institute and Hospital | Gastric Carcinoma | 12/20 | 12/25 | | |
PERSIST, NCT04982939: Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 210 | RoW | Sintilimab, IBI308, S-1, Oxaliplatin | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer, Perioperative, Sintilimab | 06/23 | 06/24 | | |
NCT05627414: Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer |
|
|
| Not yet recruiting | 2 | 30 | NA | Disitamab Vedotin, RC48, Sintilimab, TYVYT, S-1, Tegafur，Gimeracil and Oteracil Potassium Capsules, Intraperitoneal chemotherapy with paclitaxel, Paclitaxel (PTX) | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer | 06/24 | 01/25 | | |
NCT06454435: Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer |
|
|
| Not yet recruiting | 2 | 158 | RoW | Sintilimab + Fruquinitinib + S-1 plus nab-paclitaxel, Sintilimab + S-1 plus nab-paclitaxel | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 06/26 | 06/27 | | |
AK104-219, NCT05960955: Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 2 | 90 | RoW | Cadonilimab, AK117, Oxaliplatin, Tegafur-gimeracil-oteracil potassium, Docetaxel, 5-Fluorouracil | Akeso | Resectable Gastric or Gastroesophageal Junction Adenocarcinoma | 11/24 | 11/27 | | |
NCT06560528: Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression |
|
|
| Recruiting | 2 | 40 | RoW | combination with Disitamab Vedotin and with Tislelizumab and Capecitabine | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 09/27 | 09/28 | | |
NCT05853172: Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer |
|
|
| Recruiting | 2 | 30 | RoW | AK104, Apatinib, Paclitaxel, S-1 | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer | 03/25 | 12/25 | | |
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies |
|
|
| Recruiting | 1 | 258 | Europe, US, RoW | NB003 tablets | Ningbo Newbay Technology Development Co., Ltd | Advanced Solid Tumor | 07/25 | 12/25 | | |
CGCT-01, NCT02130752: Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery |
|
|
| Recruiting | N/A | 430 | RoW | Monopolar electrocautery, Ultrasonic scalpel | West China Hospital | Gastric Cancer, Surgery, Ultrasonic Scalpel, Monopolar Electrocautery, Operation Time, Blood Loss, Surgical, Quality of Life, External Causes of Morbidity and Mortality | 10/19 | 10/22 | | |
TOP1, NCT04108494: A Trial of Total Versus Partial Omentectomy for Advanced Gastric Cancer in Gastrectomy |
|
|
| Recruiting | N/A | 418 | RoW | Type of omentectomy | Tianjin Medical University Cancer Institute and Hospital | Gastric Cancer | 12/20 | 12/25 | | |
| Hao, Jihui |
NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 5 | RoW | Fluzoparib, SHR3162, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Pancreatic Cancer | 02/22 | 02/22 | | |
BESTPOP, NCT05594927: Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, ) |
|
|
| Recruiting | 3 | 261 | RoW | Icaritin, Huachansu | Beijing Shenogen Biomedical Co., Ltd | Hepatocellular Carcinoma | 08/25 | 08/25 | | |
NCT05884255: An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors. |
|
|
| Recruiting | 3 | 220 | RoW | Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide, long-acting Octreotide. | Jiangsu HengRui Medicine Co., Ltd. | Advanced Gastroenteropancreatic Neuroendocrine Tumor | 12/26 | 10/30 | | |
| Not yet recruiting | 2/3 | 146 | RoW | Nimotuzumab, h-R3, GX, Placebo | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Cancer | 05/27 | 05/27 | | |
2023-012-00CH1, NCT06361888: A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer |
|
|
| Recruiting | 2/3 | 482 | RoW | Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine, Nab-paclitaxel Plus Gemcitabine, Surufatinib with Nab-paclitaxel, and Gemcitabine | Hutchmed | Metastatic Pancreatic Cancer | 08/27 | 08/27 | | |
NCT04808687: Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer |
|
|
| Recruiting | 2 | 72 | RoW | Nab paclitaxel and S-1 | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Neoplasms | 02/23 | 02/24 | | |
NCT06405685: Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis |
|
|
| Recruiting | 2 | 30 | RoW | Nimotuzumab, h-R3, AG | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Cancer | 10/25 | 10/25 | | |
NCT04814485: Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer |
|
|
| Recruiting | 2 | 39 | RoW | SHR-1020+albumin-bound paclitaxel, Nab-paclitaxel， Paclitaxel-albumin | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Cancer | 07/23 | 07/23 | | |
NCT06413017: Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure |
|
|
| Recruiting | 2 | 30 | RoW | Nimotuzumab, h-R3, ICIs(Immune checkpoint inhibitors), PD-1 or PD-L1 | Tianjin Medical University Cancer Institute and Hospital | HCC | 07/25 | 12/25 | | |
NCT05208177: A Study of SHR-1802 in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 2 | 124 | RoW | SHR-1802＋camrelizumab + famitinib | Jiangsu HengRui Medicine Co., Ltd. | Advanced Solid Tumor | 12/23 | 12/24 | | |
NCT05947825: Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients |
|
|
| Not yet recruiting | 2 | 30 | NA | Combination of sitagliptin+ gemcitabine + nab-paclitaxel | Tianjin Medical University Cancer Institute and Hospital | PDAC - Pancreatic Ductal Adenocarcinoma | 08/24 | 08/24 | | |
NCT05908747: Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer |
|
|
| Recruiting | 2 | 29 | RoW | surufatinib + gemcitabine + nab-paclitaxel | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Cancer | 05/25 | 05/26 | | |
NCT05559541: Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 102 | RoW | AK119, AK104 | Akeso | Solid Tumor, Adult | 03/24 | 09/24 | | |
| Not yet recruiting | 1/2 | 96 | NA | Irinotecan liposome injection, Nal-IRI, Oxaliplatin, Eloxatin, 5-Fluorouracil, 5-FU, flurouracil, Adrucil, Leucovorin, Folinic Acid, SBRT | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Cancer | 04/26 | 12/27 | | |
| Active, not recruiting | 1/2 | 220 | RoW | SHR-A1921； | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumor | 04/25 | 02/26 | | |
NCT05868876: A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1a/1b | 205 | RoW | AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion | Akeso | Advanced Malignant Tumors | 11/25 | 02/26 | | |
NCT04482257: Bioequivalence Study of Irinotecan Liposome Injection in Chinese Advanced Pancreatic Cancer. |
|
|
| Recruiting | 1 | 48 | RoW | Irinotecan Liposome Injection combined with 5-FU/LV | CSPC Ouyi Pharmaceutical Co., Ltd. | Advanced Pancreatic Cancer | 12/20 | 03/21 | | |
NCT05173792: Study of AK119 in Subjects With Advanced Solid Tumors |
|
|
| Completed | 1 | 16 | RoW | AK119 | Akeso | Solid Tumor | 05/23 | 05/23 | | |
NCT05149027: A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combine With Toripalimab in Patients With Advanced HCC and Other Solid Tumors |
|
|
| Not yet recruiting | 1 | 67 | NA | HBM4003 and Triprilimab | Harbour BioMed (Guangzhou) Co. Ltd. | Solid Tumors | 05/24 | 05/24 | | |
NCT05125523: A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 264 | RoW | Sirolimus for Injection (Albumin Bound) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumors | 06/24 | 11/24 | | |
| Recruiting | 1 | 65 | RoW | TQB3824 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Cancer | 08/24 | 12/24 | | |
NCT05740202: A Trial of SHR-7367 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 182 | RoW | SHR-7367 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 11/25 | 11/25 | | |
| Recruiting | N/A | 10000 | RoW | | Shanghai Jiao Tong University School of Medicine, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, First Affiliated Hospital Bengbu Medical College, LanZhou University, Henan Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, The Second Affiliated Hospital of Harbin Medical University, First Affiliated Hospital of Harbin Medical University, Harbin Medical University, The First Hospital of Jilin University, Second Hospital of Jilin University, China-Japan Union Hospital, Jilin University, The First People's Hospital of Changzhou, Changzhou No.2 People's Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, The First People's Hospital of Taicang, Wuxi Second People's Hospital, Xuzhou Central Hospital, Second Affiliated Hospital of Suzhou University, Affiliated Hospital of Nantong University, The First People's Hospital of Nantong, The Affiliated Hospital of Xuzhou Medical University, Second Affiliated Hospital of Nanchang University, The First Affiliated Hospital of Nanchang University, Jiangxi Provincial People's Hopital, Shengjing Hospital, Baotou Central Hospital, Qinghai People's Hospital, Changzhi Medical College, The First Affiliated Hospital of Shanxi Medical University, Shanxi Provincial Cancer Hospital, First Affiliated Hospital Xi'an Jiaotong University, Eastern Hepatobiliary Surgery Hospital, Shanghai Fengxian District Central Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Zhongshan Hospital, Shanghai Pudong Hospital, Central Hospital of Minhang District, Shanghai, Putuo District People's Hospital of Shanghai, Xinhua (Chongming) Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Tianjin Medical University Cancer Hospital, First Affiliated Hospital of Xinjiang Medical University, The First Affiliated Hospital of Kunming Medical College, Yinzhou Hospital Affiliated to Medical School of Ningbo University, Shaoxing Second Hospital, Shaoxing People's Hospital, First Affiliated Hospital of Wenzhou Medical University, Sir Run Run Shaw Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Cancer Hospital, Huizhou Municipal Central Hospital, Ningbo No. 1 Hospital, People's Hospital of Hunan Province, Hainan People's Hospital, Taizhou Municipal Hospital, Xinghua City People's Hospital, Tongliao City Hospital, Jiangxi Provincial Cancer Hospital, Shandong Provincial Hospital, Qilu Hospital of Shandong University, The Affiliated Hospital of Qingdao University, Xijing Hospital | Gallbladder Neoplasms | 12/22 | 12/25 | | |
NCT05997147: A Preoperative Model to Predict the Lymphovascular Invasion in Pancreatic Ductal Adenocarcinoma |
|
|
| Recruiting | N/A | 1009 | RoW | | Tianjin Medical University Cancer Institute and Hospital | Predictive Cancer Model, Pancreas Cancer | 08/23 | 08/23 | | |
NCT06208436: The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer |
|
|
| Recruiting | N/A | 250 | RoW | Adjuvant chemotherapy | Tianjin Medical University Cancer Institute and Hospital | Pancreas Cancer, Chemotherapy | 02/24 | 02/24 | | |
NCT06717022: A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors |
|
|
| Recruiting | N/A | 24 | RoW | CHT102 allogeneic CAR T cells | Tianjin Medical University Cancer Institute and Hospital, Nanjing Calmhome Cell & Gene Engineering Institute Co., Ltd. | Mesothelin Positive Tumors | 06/26 | 05/39 | | |
